Frazier Life Sciences X, L.P. → NEWAMSTERDAM PHARMA COMPANY N.V. NAMSW

Stake: 8.70% Shares: 7,329,857 CUSIP: N62509109 Class: Ordinary Shares, nominal value EUR0.12 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 1.00

42 shares short · +2.4% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

2 holders · $142.56M

Duquesne Family OfficeViking Global

Other 13D/G Filings on NEWAMSTERDAM PHARMA COMPANY N.V.

Filed	Form	Filer	Stake	Shares
2026-05-14	SCHEDULE 13D/A	BCLS II Investco, LP	—	2,059,896	view →
2025-11-07	SCHEDULE	BCLS II Investco, LP	9.99%	11,422,504	view →
2025-09-30	SCHEDULE	Forbion Capital Fund IV Cooperatief U.A.	8.30%	9,316,914	view →
2023-07-07	SC	Forbion Capital Fund IV Cooperatief U.A.	—	—	view →
2023-06-13	SC	BCLS II Investco, LP	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →